Samarth Lifesciences Attracts Private Equity Interest Amid Reports of Potential Quadria Investment

Private Equity Firms Eye Samarth Lifesciences Acquisition

Four to five private equity firms, including Quadria Capital, are evaluating a potential acquisition of a controlling 80-85 percent stake in Samarth Lifesciences, a Mumbai-based pharmaceutical company. The transaction could value the company at around Rs 4,500 crore, according to an Economic Times report released on Thursday.

The proposed deal would see the promoters retain a 15-20 percent holding in the company. Investment bank O3 Capital has been mandated to advise the promoters on the deal process.

Samarth Lifesciences is seeking fresh capital to fund its next phase of expansion, including new manufacturing facilities and a stronger domestic presence. The company has built a diversified portfolio spanning critical care, cardiac, anti-infectives, urology, oncology, and gynaecology therapies since its founding in 1963 by Gunwantlal Shah.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Samarth Lifesciences has drawn increasing interest from private equity investors due to its improved performance over the past decade. The company is seeking a valuation multiple of nearly 30 times earnings, which some investors consider expensive. Samarth is estimated to have posted EBITDA of Rs 160-170 crore in FY26.

The company reported revenue of Rs 727 crore, with compounded annual growth of 16 percent, higher than the industry growth rate of 10-12 percent, based on data from PharmaTrac. Among its leading products are Caprin, an anticoagulant injection used to prevent blood clots, which recorded Rs 74 crore in moving annual turnover as of March 2026 and delivered a five-year CAGR of 27 percent.

Samarth has developed a strong position in the injectables and sterile products segment, an area known for relatively fewer competitors and higher margins. The company has also expanded internationally, with operations across the UK, South America, Southeast Asia, and Africa.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Quadria Capital, which focuses on healthcare investments, manages more than $4.2 billion in assets across 29 investments in South and Southeast Asia. In India, the firm owns around a 15 percent stake in Encube Ethicals, a company specialising in topical formulations across dermatology and reproductive healthcare. A planned stake sale in Encube Ethicals by its promoters and Quadria had also fallen through recently due to valuation disagreements.